EMA Authorised: Kigabeq (vigabatrin) — ORPHELIA Pharma

View source ↗

Summary

EMA has authorised Kigabeq (vigabatrin) for infantile spasms and partial epilepsies, with ORPHELIA Pharma as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Spasms
• Partial Epilepsy

Drugs mentioned

• Kigabeq (vigabatrin)

Snippet

Status: Authorised. Therapeutic area: Spasms, Infantile;Epilepsies, Partial. MAH: ORPHELIA Pharma. Decision date: 22/07/2026